Core Viewpoint - Lepu Biopharma-B (02157) has seen a significant stock price increase of over 12%, reaching HKD 9.33 with a trading volume of HKD 448 million, following the announcement of new clinical trials for its drug candidates [1] Group 1: Clinical Trials and Developments - Lepu Biopharma has registered a Phase III clinical trial for MRG004A, which will compare its efficacy and safety against a placebo in patients with advanced pancreatic cancer [1] - The Phase III trial aims to explore the potential of MRG004A as a new treatment option for pancreatic cancer patients [1] - The company has also initiated a Phase I/II clinical study for MRG007, focusing on its safety, tolerability, efficacy, and pharmacokinetics in patients with unresectable locally advanced or metastatic solid tumors [1] Group 2: Licensing and Financial Aspects - The rights for MRG007 outside Greater China have been licensed to ArriVent, with an upfront payment and recent milestone payments totaling USD 47 million [1] - Lepu Biopharma is entitled to receive up to USD 1.16 billion in milestone payments and sales royalties from the licensing agreement [1]
港股异动 | 乐普生物-B(02157)涨幅扩大逾12% MRG004A启动III期临床 MRG007完成首例患者入组